Updated
- Log In
- Newsletters
-
Subscribe
Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Biotechnology
3 Small Biotechs That Came Up Big on Thursday
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
Eli Lilly Could Hit New Highs, but Market Weakness Could Mute Gains
It shouldn't hurt that the drugmaker beat third-quarter estimates and raised its profit guidance for all of 2018.
Small Biotechs Finally Join in Market Rebound
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
Why Investors Should Favor Smaller Biotech Companies
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
Novartis Secures Prostate Cancer Treatment With Endocyte Deal
The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
As Canada OKs Pot, Research Advances Could Follow
As Canada becomes the second country after Uruguay to allow recreational use of cannabis, advances in pot research could follow.
Biotech and Broadway Come Together to Fight Cancer
Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.
3 Biotech Stocks Ready to Burn Up
Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.
3 Biotech Stock Favorites to Bet on Today: Top Analysts
Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.
This Company Is at the Center of Insider Trading Charges Against Rep. Collins
Innate Immunotherapeutics of Australia is the biopharmaceutical company at the center of the insider trading charges leveled against New York Rep. Chris Collins.